Doubt it will go red, but if you read historical posts, especially mine, you'll see alot obout MM behavior on NVLX particularly ETMM. THe only way i been able to get him to move historically is coming w/ bid over $2k at ask, then he usually give small partial fill and move up
Nuvilex, Inc. Announces Favorable Initial Test Results of Natural Product Cancer Agent Alternia
1 hours 12 minutes ago - WSW via Comtex
WorldStockWire
Nuvilex, Inc. (OTCQB: NVLX), in conjunction with its subsidiary Knock-Out Technologies, Ltd. and joint venture partner Legacy Biotechnologies, Inc., report preliminary study findings undertaken with Alternia(TM), Nuvilex's natural product cancer agent formulation.
Initial studies, carried out at a prestigious research center in Georgia, suggested Alternia(TM) had potential to cause alterations in cell division and initiate apoptosis in cancer cells, a series of events typically leading to cell death. In cancer research, agents that affect cell division and cause apoptosis, or cell death, are often studied in greater detail because they may lead to effective therapies. The potentially favorable outcomes of the initial studies prompted Nuvilex management to pursue additional testing.
As a result, the effect of Alternia(TM) was assessed for its effect on cancer cell line growth at a leading cancer center in Florida. Significantly, Alternia(TM) caused alterations in cell cycle arrest and the ability to induce apoptosis in some cell lines, indicating the need for additional studies. Preliminary animal testing was carried out at Discovery and Imaging Services (MIR), a subsidiary of Charles River Laboratories, Tier 1 specialists in pre-clinical laboratory services. Results of the animal tests provided initial information on toxicity, potential future dosages and maximum tolerated dose, providing insight into future directions for this agent. Future testing will include additional cell line and animal studies to determine specific cancer cell types which Alternia(TM) may be effective against and aid parameter determination for prospective clinical trials.
Nuvilex's Chief Executive, Dr. Robert F. Ryan, commented, "We are still in the developmental stages, but initial testing with Alternia(TM) allows us to consider directions to advance its development. We plan to investigate it further and assess its potential for human use, as well as working to procure adequate resources, including grant acquisition, to ensure its ability to be studied. Nuvilex greatly appreciates Legacy Biotechnologies' funding of Alternia(TM) testing and their role in its development, allowing us to devote primary resources to advancing existing products and sales, establishing new products and enhancing shareholder value."
We at Nuvilex are...
a Green Company believing in "Good for You, Good for the Environment" and are expanding our natural product lines and entering into biotechnology (www.nuvilex.com). Current products include Cinnergen(TM) for healthy glucose maintenance; Cinnechol(TM) to maintain healthy lipids and cardiovasculature; Cinnsational(TM) to decrease detrimental alcohol effects; Talsyn(TM) for keloids, erythema and scar management; NumaDerm(TM) cosmetic products; Citroxin(TM) and Oraphyte(TM) antimicrobial and antinematodal agents; Reme-Flu(TM), Legacy Biotechnologies' flu combating regimen; and Virgin(R) and Infinitink(R), heavy-metal-free tattoo inks.
Safe Harbor Statement
This information may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Nuvilex's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.
Robert Ryan
Nuvilex
7702 E. Doubletree Ranch Road
Scottsdale, AZ 85258
USA
Phone: 480-348-8050
News 
Market Data 
Discover 
AI
